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Potassium channels act as chemosensors
for solute transporters
Rίan W. Manville1 & Geoffrey W. Abbott1✉
Potassium channels form physical complexes with solute transporters in vivo, yet little is
known about their range of possible signaling modalities and the underlying mechanisms. The
KCNQ2/3 potassium channel, which generates neuronal M-current, is voltage-gated and its
activity is also stimulated by binding of various small molecules. KCNQ2/3 forms reciprocally
regulating complexes with sodium-coupled myo-inositol transporters (SMITs) in mammalian
neurons. Here, we report that the neurotransmitter γ-aminobutyric acid (GABA) and other
small molecules directly regulate myo-inositol transport in rat dorsal root ganglia, and
by human SMIT1-KCNQ2/3 complexes in vitro, by inducing a distinct KCNQ2/3 pore
conformation. Reciprocally, SMIT1 tunes KCNQ2/3 sensing of GABA and related metabolites.
Ion permeation and mutagenesis studies suggest that SMIT1 and GABA similarly alter
KCNQ2/3 pore conformation but via different KCNQ subunits and molecular mechanisms.
KCNQ channels therefore act as chemosensors to enable co-assembled myo-inositol
transporters to respond to diverse stimuli including neurotransmitters, metabolites and drugs.
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K
+ efflux through K+-selective channels, including voltage-
gated potassium (Kv) channels, represents a major inhibitory
force in excitable cells, regulating resting membrane poten-
tial, terminating action potentials, and tuning firing frequency. In
the neurons of the majority of multicellular organisms, including
vertebrates, the M-current, a muscarinic-inhibited Kv current1
generated by KCNQ (Kv7) family Kv channels (M-channels)2,3, is
required for control of neuronal excitability4. The M-current
is generated primarily by KCNQ2 and KCNQ3 subunits, pre-
dominantly in the form of heteromeric (KCNQ2/3) channels4,
but homomers also exist in vivo and KCNQ4 and KCNQ5 also
contribute5. KCNQ2/3 channels are muscarinic acetylcholine
receptor-regulated, non-inactivating, and open at relatively hyper-
polarized membrane potentials. They are therefore uniquely placed
to regulate neuronal excitability. Hence, KCNQ2/3 gating state
(open versus closed) dictates phasic versus tonic firing of neurons4.
We recently discovered a novel form of regulation for some
neuronal KCNQ channels. The primary inhibitory neuro-
transmitter in higher animals, γ-aminobutyric acid (GABA) is
well-known for its essential role in inhibitory neurotransmission,
whereby it activates canonical GABA receptors including GABAA
receptors (GABAARs), which are ligand-gated, chloride-selective
channels that open to suppress neuronal excitability6. The
other major canonical class of GABA receptors, GABABRs, are
G-protein-coupled receptors that, upon GABA binding, activate
other proteins, including certain types of K+ channel (but not
KCNQs)7. Unexpectedly, we found that some members of the
KCNQ Kv channel subfamily (isoforms 2–5), which bear no
resemblance in structure or topology to canonical GABARs,
can also directly bind GABA, via a tryptophan residue on
transmembrane segment 5 (S5). Furthermore, we found that in
KCNQ3, KCNQ5, and KCNQ2/3 heteromers, GABA binding
results in channel activation, and thus cellular hyperpolarization8.
Because some KCNQ channels are sensitive to physiologically
relevant (submicromolar) concentrations of GABA, GABA
activation of KCNQ channels therefore presents an additional
mechanism for GABA-dependent inhibition in the CNS. Interest-
ingly, KCNQ2 subunits are enriched in GABAergic neurons, in
particular those important for regulating network oscillations and
synchrony9. Presynaptic KCNQ2/3 channels can modulate gluta-
mate and GABA release, and may act pre- and post-synaptically to
suppress neuronal excitability10,11. Further, Kcnq2 deficient mice
exhibit abnormal GABAergic synaptic transmission12. Vertebrate
nervous systems also contain many GABA analogues and meta-
bolites, some of which do not modulate canonical GABARs, but can
activate select KCNQ isoforms. One example is β-hydroxybutyrate
(BHB), a ketone body that accumulates during ketosis and is
thought to underlie antiepileptic effects of fasting and ketogenic
diets; another is γ-amino-β-hydroxybutyric acid (GABOB), which
acts as a KCNQ2/3 high-affinity partial agonist8.
KCNQ2/3 channels can form complexes with sodium-coupled
myo-inositol transporters SMIT1 and SMIT213,14, which use the
downhill Na+ gradient to transport into cells myo-inositol, an
important osmolyte and precursor of cell signaling molecules
including phosphatidylinositol 4,5-bisphosphate (PIP2), which is
highly influential in the gating of KCNQ and other ion chan-
nels15–18. We previously detected complex formation between
KCNQ2, KCNQ3, SMIT1, and/or SMIT2 in mouse neuron axon
initial segments, and in rat and mouse sciatic nerve nodes of
Ranvier14. SMIT1 and SMIT2 each negatively shift the voltage
dependence of KCNQ2/3 channel activation, with superficially
similar effects to GABA activation. This effect of SMIT1 and
SMIT2 on KCNQ2/3 voltage dependence occurs by physical
interaction with the KCNQ2/3 channel pore, without the need
for myo-inositol. However, addition of myo-inositol further
augments KCNQ2/3 activation when in complexes with SMIT1
(or SMIT2) by providing a substrate for local production of PIP2.
In addition, SMIT1 co-assembly alters the pharmacology of
KCNQ2 and KCNQ2/3 channels13,14.
Here, we report that GABA and its metabolites can modulate
myo-inositol uptake of SMIT1 via chemosensing by co-assembled
KCNQ2/3, and we identify molecular mechanistic determinants
of this cross-talk, uncovering a, to our knowledge, novel paradigm
for cellular signaling.
Results
GABA and related metabolites regulate SMIT1 via KCNQ2/3.
KCNQ channels, like all Kv channels, form as tetramers of α
subunits, each subunit of which contains six transmembrane (S)
segments, split into the voltage-sensing domain (VSD, S1–4) and
the pore module (S5–6). SMIT1 and SMIT2 transporters have a
predicted 14 transmembrane segment topology (Fig. 1a). As we
previously found that KCNQ2/3 channels co-localize with SMIT1
in rodent neurons and co-assemble with SMIT1 in vitro14, we
first quantified the effects of GABA on myo-inositol uptake of
whole dorsal root ganglia (DRG) isolated from postnatal day 8
rats. GABA (100 µM) reduced [3H]myo-inositol uptake >twofold
(Fig. 1b). In Xenopus oocyte expression studies, heterologously
expressed SMIT1 activity was insensitive to GABA (100 µM)
when expressed alone (Fig. 1c). In contrast, when co-expressed
with KCNQ2/3, SMIT1 activity was inhibited >twofold, repli-
cating our observations from rat DRG. Glutamate, which has no
effect on KCNQ2/3 channels8, had no effect on SMIT1 activity in
the presence of KCNQ2/3. However, β-hydroxybutyrate (BHB),
γ-aminohydroxybutyrate (GABOB), and the anticonvulsant reti-
gabine, each of which, like GABA, activates KCNQ2/3 by negative
shifting its voltage dependence of activation8, each inhibited
SMIT1 activity in the presence of KCNQ2/3 (Fig. 1d). We pre-
viously found that an S5 tryptophan conserved in neuronal
KCNQs (e.g., W265 in KCNQ3) is required for binding to and
activation of KCNQs by GABA8. Here, mutation to leucine of
KCNQ2–W236 and KCNQ3–W265 in KCNQ2/3 channels pre-
vented GABA inhibition of co-expressed SMIT1 activity (Fig. 1e).
Thus, GABA binding to the S5 tryptophan of KCNQ2/3 channels
inhibits myo-inositol uptake by co-expressed SMIT1.
SMIT1 alters small molecule effects on KCNQ2/3 gating.
Heterologous co-expression in Xenopus laevis oocytes of human
KCNQ2/3 channels and SMIT1 generated slow-activating, slow
deactivating, non-inactivating voltage-dependent K+ currents,
which we measured using two-electrode voltage clamp (TEVC)
(Fig. 2a). Bath application of GABA (10 nM–10mM) increased the
peak tail currents, negative shifted the voltage dependence of acti-
vation of KCNQ2/3 channels (Fig. 2a, b) and increased activation
rate (Fig. 2c), as we previously found for GABA effects on KCNQ2/
3 in the absence of SMIT18. SMIT1 did not alter the maximal effects
of GABA on KCNQ2/3 currents; however, SMIT1 co-expression
reduced the potency of GABA with respect to KCNQ2/3 activation
threefold, as measured by current fold increase at −60mV, where
changes are higher than at more depolarized voltages but accurately
quantifiable (KCNQ2/3, EC50= 1.1 ± 0.39 µM GABA; KCNQ2/
3–SMIT1, EC50= 3.0 ± 0.67 µM GABA) (Fig. 1d). We observed an
approximately similar (fourfold) reduction in KCNQ2/3 GABA
sensitivity upon SMIT1 co-expression when we quantified the
shift in voltage dependence of activation (ΔV0.5activation) (KCNQ2/3,
EC50= 137 ± 23 nM GABA; KCNQ2/3–SMIT1, EC50= 593 ± 125
nM GABA) (Fig. 1e).
KCNQ2/3–SMIT1 complexes were also sensitive to BHB, as we
previously observed for KCNQ2/3; in the presence of SMIT1,
BHB increased the peak tail current, negative shifted the voltage
dependence of KCNQ2/3 activation (Fig. 2g) and speeded
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KCNQ2/3 activation (Fig. 2h). SMIT1 modulated the effects of
BHB on KCNQ2/3, but differently to effects for GABA. Thus,
SMIT1 increased the maximal efficacy of BHB 3-fold with respect
to KCNQ2/3, yielding an maximal 8-fold increase in current at
−60 mV (Fig. 2i) but reduced the BHB potency 60-fold as
quantified by fold increase at −60 mV (KCNQ2/3–SMIT1, BHB
EC50= 16.5 ± 0.46 µM, versus 0.26 ± 0.07 µM for KCNQ2/3 with-
out SMIT1) (Fig. 2i) or 13-fold as quantified by ΔV0.5activation
(KCNQ2/3–SMIT1, BHB EC50= 10.2 ± 0.31 µM, versus 0.79 ±
0.30 µM for KCNQ2/3 without SMIT1) (Fig. 2j).
GABOB is a high-affinity partial agonist of KCNQ2/3
channels8. GABOB effects on KCNQ2/3–SMIT1 voltage depen-
dence and activation rate were minimal (Fig. 2k–n). SMIT1
appears to reduce KCNQ2/3 sensitivity, by threefold as quantified
by ΔV0.5activation (KCNQ2/3–SMIT1 GABOB EC50= 304 ±
100 nM, versus 89.1 ± 10 nM for KCNQ2/3 alone) (Fig. 2o).
The capacity of SMIT1 to tune KCNQ2/3 sensitivity to GABA
and related metabolites suggests that SMIT1 impinges on the
KCNQ2/3 binding site for these molecules.
GABA and SMIT1 similarly alter KCNQ2/3 ion selectivity. We
previously found that SMIT1 binds to the KCNQ2 pore module
and decreases KCNQ2/3K+ selectivity, producing a relative
increase in Na+ and Cs+ permeability—evidence of an effect of
SMIT1 binding on KCNQ2/3 pore conformation13. Here, we
found that GABA, which binds to a conserved tryptophan in S5
within the pore module of KCNQ2–5 (e.g., W265 in KCNQ3),
also increases KCNQ2/3 Na+ and Cs+ permeability relative to
that of K+ (Fig. 3a–c). The results suggest that there are some
common features to GABA and SMIT1 effects on KCNQ2/3 pore
conformation. We next tested the effects of GABA on homomeric
KCNQs (Fig. 3d–l). We previously found that while GABA binds
to the S5 tryptophan of both KCNQ2 (W236) and KCNQ3
(W265), GABA activates homomeric KCNQ3, but not homo-
meric KCNQ28. Here, we found that GABA has no effect on the
ion selectivity of homomeric KCNQ2 (Fig. 3d–f). In contrast,
GABA increased the Na+ and Cs+ permeability of homomeric
KCNQ3*—an expression-optimized KCNQ3 mutant (A315T),
previously found to give robust KCNQ3 currents without altering
other fundamental channel properties19 (Fig. 3g–i). As an addi-
tional control we examined KCNQ4, which also binds GABA but
is not activated by it8. GABA also had no effect on KCNQ4 ion
selectivity (Fig. 3j–l). Thus, the current-potentiating effects of
GABA occur concomitant to a shift in ion selectivity (as we
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observe for KCNQ3 homomers and KCNQ2/3 heteromers); the
selectivity shift does not occur in KCNQs that are not activated by
GABA, even when GABA can bind to them (homomeric KCNQ2
and KCNQ4). These data suggest that the ion selectivity shift
signals a conformational shift in the pore that occurs upon acti-
vation by GABA.
KCNQ3 is structurally primed to be the GABA sensor for
SMIT1. The effects of SMIT1 on homomeric KCNQ3 channels
were not previously reported. Here, we found that SMIT1 positively
shifts the voltage dependence of KCNQ3* (Fig. 4a–d), slows its
activation (Fig. 4e) and depolarizes KCNQ3*-expressing oocytes
(Fig. 4f), i.e., SMIT1 impedes voltage-dependent KCNQ3* activa-
tion. This is the opposite of SMIT1 effects on KCNQ2 and KCNQ2/
3, as we previously reported13. Comparing next the effects of SMIT1
on homomeric KCNQ2 and KCNQ3* relative ion permeability, we
found that SMIT1 greatly increases the relative Na+ and Cs+
permeation compared to K+ of KCNQ2 (Fig. 4g–i), but not
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KCNQ3* (Fig. 4j–l). This is again consistent with the increased Na+
and Cs+ permeability being the signature of an alternate pore
conformation that arises when the voltage dependence of KCNQ
channel activation is negative shifted, either by GABA or by SMIT1
(Fig. 3 and ref. 13). This suggests that while GABA activates and
alters pore properties of KCNQ2/3 channels via KCNQ3, SMIT1
activates and alters pore properties of KCNQ2/3 via KCNQ2.
Furthermore, the results suggest that by maintaining its baseline
pore conformation despite interaction with SMIT1, KCNQ3 (but
not KCNQ2) is structurally primed to respond to GABA and
communicate the effects of GABA binding to SMIT1 to regulate
SMIT1 function. Consistent with this hypothesis, KCNQ3*–SMIT1
but not KCNQ2–SMIT1 was responsive to GABA, with the func-
tional output being an approximately twofold reduction in SMIT1
myo-inositol uptake (Fig. 4m, n), similar to effects of GABA on
KCNQ2/3–SMIT1 complexes (Fig. 1d).
SMIT1 permits KCNQs to distinguish BHB from GABA and
GABOB. We previously showed that, as for GABA, BHB acti-
vates homomeric KCNQ3* but not KCNQ28. Strikingly, here we
found that while KCNQ3* but not KCNQ2 can communicate the
GABA binding event to co-expressed SMIT1 to alter its activity,
for BHB the isoform selectivity is reversed. Thus, BHB inhibits
myo-inositol transport activity of SMIT1 when co-expressed with
KCNQ2, but not KCNQ3*. In contrast, for GABOB, as for
GABA, KCNQ3* but not KCNQ2 conferred sensitivity to SMIT1
(Fig. 4m, n). Thus, SMIT1 enables KCNQs to distinguish BHB
from the structurally highly similar (Fig. 2) GABA and GABOB.
An S4–5 arginine is required for SMIT1–KCNQ2/3 commu-
nication. We previously found that GABA binds to the S5-
located KCNQ2–W236 and KCNQ3–W265 (Fig. 5a, b), and that
activation of KCNQ2/3 channels requires KCNQ3–W265
(KCNQ2 binds GABA but is not activated by it)8. We showed
earlier that complexes formed by SMIT1 and heteromeric
mutant W236L–KCNQ2/W265L–KCNQ3 channels do not
respond to GABA (Fig. 1e) which is consistent with the role
of the S5 W residues in GABA binding. However,
W236L–KCNQ2/W265L–KCNQ3 channels remain sensitive to
SMIT1, which negative shifts their midpoint voltage dependence
of activation (Fig. 5c–f) and hyperpolarizes W236L–KCNQ2/
W265L–KCNQ3-expressing oocytes (Fig. 5g) as we previously
found for wild-type KCNQ2/3 channels13.
We also recently found that some plant metabolites can
hyperpolarize KCNQ channel activation voltage dependence by
binding to an arginine (e.g., R242 in KCNQ3) at the foot of S4,
abutting the S4–5 linker (Fig. 5b)20–23. More recently, we found
that this arginine also influences GABA binding23. Here, the
activity of KCNQ2/3 channels with the S4–5 arginine mutated to
alanine (KCNQ2–R213A/KCNQ3–R242A) was strongly inhibited
by SMIT1 (Fig. 5h, i), in contrast to effects for wild-type13 or WL/
WL (Fig. 5c–g) KCNQ2/3. While the low current magnitude of
the resultant channels precluded accurate quantification of
voltage dependence, SMIT1 co-expression positive shifted the
resting membrane potential of KCNQ2–R213A/KCNQ3–R242A
channels (Fig. 5j), the opposite of effects on wild-type13 or WL/
WL (Fig. 5c–g) KCNQ2/3. Thus, we conclude that GABA binding
to the S5 W causes a conformational shift in KCNQ2/3 channels
that is communicated to co-assembled SMIT1 via residues
other than the S5 W, likely including R213/R242. In accord with
this hypothesis, KCNQ2–R213A/KCNQ3–R242A channels were
unable to modulate either SMIT1 myo-inositol transport, or the
regulation of this process by GABA (Fig. 5k).
Discussion
An increasing number of potassium channel-transporter (“chan-
sporter”) complexes are being uncovered. Thus far, the KCNQ
potassium channel family appears particularly influential in this
area, but whether this stems from an inherent proclivity of KCNQs
to participate in chansporter complexes, or an investigational bias
arising from the early KCNQ studies in this area is not yet known.
KCNQ1 physically interacts with SMIT1 in the choroid plexus,
in tripartite complexes with KCNE2, and in vitro is thought to
also form complexes with the structurally related myo-inositol
transporter, SMIT213,24. KCNQ2/3 complexes are now known to
interact with SMIT1 and SMIT213,14, and DAT and GLT1 (sodium-
coupled dopamine and glutamate transporters, respectively)25,26 in
the brain and/or peripheral nervous system.
The single Drosophila KCNQ gene product, dKCNQ, interacts
with cupcake (dSLC5A11), a non-transporting orthologue of
SMIT2 that probably acts as a glucose sensor to help control
feeding behavior via its effect on dKCNQ activity27. Similar to
what we found for human SMIT2 with KCNQ124, dSLC5A11
inhibits dKCNQ activity; increased cupcake expression in the
vinegar fly brain inhibits neuronal dKCNQ activity. This pro-
motes feeding and other hunger-driven activities27.
In complexes with the DAT and GLT1 transporters, KCNQ2/3
channels are thought to counteract the depolarizing force of sodium
co-transport into neurons, facilitating optimal neurotransmitter
transport through DAT and GLT1 while also preventing excessive
membrane depolarization. As previously found for KCNQ–SMIT
chansporter complexes24, inhibition of the co-assembled KCNQ2/3
channels using the small molecule XE991 removed the augmenting
effects of KCNQ2/3 on DAT and GLT1 transport activity. Com-
plexes formed from DAT and GLT1 with KCNQ2/3 may arise in
Fig. 2 SMIT1 alters effects of GABA on KCNQ2/KCNQ3 channels. All error bars indicate SEM. a Mean traces for KCNQ2/KCNQ3 (Q2/Q3) co-expressed
with SMIT1 (S1) in the absence (Control) or presence of GABA (100 µM) (n= 5). Voltage protocol for this and all similar recordings in this study, inset.
Structure and electrostatic surface potential heatmap plots shown for GABA. Red, negative charge, blue, positive charge for all heatmaps in this article.
b Mean tail current (at arrow in (a)) and normalized tail current (G/Gmax) versus prepulse voltage for KCNQ2/KCNQ3–SMIT1 traces as in (a) (n= 5).
c GABA effects on KCNQ2/KCNQ3–SMIT1 activation time constant= τact (n= 5). d Voltage dependence and dose response (at −60mV) for GABA
effects on KCNQ2/KCNQ3 (red; n= 5) and KCNQ2/KCNQ3–SMIT1 (magenta; n= 6) current. e GABA dose response for effects on KCNQ2/KCNQ3
(red; n= 5) and KCNQ2/KCNQ3–SMIT1 (magenta; n= 6) activity (shift in midpoint voltage of activation). f Mean traces for KCNQ2/KCNQ3 (Q2/Q3)
co-expressed with SMIT1 (S1) in the absence (control) or presence of BHB (100 µM) (n= 5). gMean and normalized tail current (G/Gmax) versus prepulse
voltage for KCNQ2/KCNQ3–SMIT1 traces as in (f) (n= 5). h BHB effects on KCNQ2/KCNQ3–SMIT1 activation rate (n= 5). i Voltage dependence and
dose response (at −60mV) for BHB effects on KCNQ2/KCNQ3 (red) and KCNQ2/KCNQ3–SMIT1 (blue) (n= 5). j BHB dose response for effects on
KCNQ2/KCNQ3 (red) and KCNQ2/KCNQ3–SMIT1 (blue) activity (shift in midpoint voltage of activation) (n= 5). k Mean traces for KCNQ2/KCNQ3
(Q2/Q3) co-expressed with SMIT1 (S1) in the absence (control) or presence of GABOB (100 µM) (n= 5). l Mean and normalized tail current (G/Gmax)
versus prepulse voltage for KCNQ2/KCNQ3–SMIT1 traces as in (k) (n= 5).m GABOB effects on KCNQ2/KCNQ3–SMIT1 activation rate (n= 5). n Voltage
dependence and dose response (at −60mV) for GABOB effects on KCNQ2/KCNQ3 (blue; n= 5) and KCNQ2/KCNQ3–SMIT1 (orange; n= 6). o GABOB
dose response for effects on KCNQ2/KCNQ3 (blue; n= 5) and KCNQ2/KCNQ3–SMIT1 (orange; n= 6) activity (shift in midpoint voltage of activation).
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axons where the restrictive confines could necessitate complex
formation to facilitate efficient channel-transporter cross-talk25 as
we also proposed for KCNQ2/3–SMIT1/2 complexes14.
Outside the KCNQ family, the Ca2+-activated K+ channel
BK was found to form complexes with the GABA transporter
3, GAT3—another sodium-coupled transporter (encoded by
SLC6A11)—in mouse brain lysates28. Similarly, KCNA2 (Kv1.2)
interacts with the LAT1 (SLC7A5) neutral amino acid transporter
and the two co-localize in mouse neurons. LAT1 regulates
KCNA2 gating and voltage dependence, and the proteins each
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Fig. 3 GABA increases relative sodium and cesium permeability of KCNQ channels that it activates. All error bars indicate SEM; n values indicate
biologically independent experiments. a Representative traces from recordings of Xenopus laevis oocytes injected with cRNA encoding KCNQ2/3 in 100mM
K+ (voltage protocol inset). b Mean current–voltage relationship for KCNQ2/3 in 100mMK+ (black), Cs+ (blue), Rb+ (red) and Na+ (magenta; n= 5),
in the absence or presence of GABA (100 µM; n= 6) as indicated, values quantified from arrow in panel (a). c Estimated mean ion permeability relative
to that of K+ versus ionic radius (Pauling) through KCNQ2/Q3 in the absence (black; n= 5) and presence (purple; n= 6) of GABA (100 µM). *p < 0.05.
d Representative traces from recordings of oocytes injected with cRNA encoding KCNQ2 in 100mM K+. e Mean current–voltage relationship for KCNQ2 in
100mM K+ (black), Cs+ (blue), Rb+ (red), and Na+ (magenta), in the absence or presence of GABA (100 µM) as indicated; n= 5. f Estimated mean ion
permeability relative to that of K+ versus ionic radius (Pauling) through KCNQ2 in the absence (black) and presence (purple) of GABA (100 µM); n= 5.
g Representative traces from recordings of oocytes injected with cRNA encoding KCNQ3* in 100mMK+. h Mean current–voltage relationship for KCNQ3*
in 100mMK+ (black), Cs+ (blue), Rb+ (red) and Na+ (magenta), in the absence or presence of GABA (100 µM) as indicated; n= 4. i Estimated mean ion
permeability relative to that of K+ versus ionic radius (Pauling) for Na+, Rb+, and Cs+ through KCNQ3* in the absence (black) and presence (purple) of
GABA (100 µM); n= 4. *p < 0.05. j Representative traces from recordings of oocytes injected with cRNA encoding KCNQ4 in 100mM K+. k Mean
current–voltage relationship for KCNQ4 in 100mM K+ (black), Cs+ (blue), Rb+ (red), and Na+ (magenta), in the absence or presence of GABA (100 µM)
as indicated; n= 4. l Estimated mean ion permeability relative to that of K+ versus ionic radius (Pauling) through KCNQ4 in the absence (black) and
presence (purple) of GABA (100 µM); n= 4.
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alter the effects in one another of gene variants linked to devel-
opmental delay and epilepsy29.
In the present study we provide evidence that KCNQ channels
in chansporter complexes can act as a chemosensor for the
transporter, enabling the latter to respond to stimuli it does not
typically respond to, e.g., GABA, BHB, GABOB, retigabine.
Reciprocally, the transporter has the capability to tune the
response of the channel to those same stimuli, at least in the case
of SMIT1 altering how KCNQ channels sense GABA and related
metabolites.
We demonstrate that KCNQ2/3 mediates GABA regulation
of SMIT1 activity both in vitro and in ex vivo DRG. We do not
yet know the physiological role of this regulation, but it could
potentially represent a form of negative feedback regulation.
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In this model, increased local GABA concentration subdues
neuronal firing by activating KCNQ2/3, but this in turn inhibits
co-assembled SMIT1, reducing local [PIP2] and eventually
leading to KCNQ2/3 inhibition, increasing excitability once
again (see Fig. 6 for schematic).
It is important to mention that GABA binding to KCNQ2/3 is
able to overcome inhibition of KCNQ2/3 channels by PIP2
depletion and/or muscarinic receptor activation8, therefore the
potential excitatory effects of PIP2 depletion would be predicted to
come into effect only after GABA concentrations had sufficiently
subsided. This combination of effects might be required for timed
waves of excitation and inhibition, or conversely even to dampen
such oscillations, depending on the magnitude and timing of
GABA and PIP2 concentration changes. Overlaid upon this, it was
previously discovered that KCNQ2/3 channels themselves regulate
GABA release10,11, pointing to further possible layers of feedback
regulation.
SMIT1, by apparently impacting the KCNQ-binding site for
GABA and related small molecules, can tune KCNQ responses to
these important neuronal signaling moieties. Perhaps most sur-
prisingly, SMIT1 switched the KCNQ isoform selectivity of BHB
such that its binding was communicated to SMIT1 not by
KCNQ3 but by KCNQ2 (Fig. 5). We had previously found that
while KCNQ2–5 (but not KCNQ1 because it lacks the crucial S5
tryptophan) also bind GABA, only KCNQ3 and KCNQ5 respond
to GABA8. Similarly, BHB activates KCNQ2/3 heteromers and
KCNQ3* homomers, but not KCNQ2 homomers30. As we also
observed for GABA, when in complexes with KCNQ2/3 hetero-
mers, SMIT1 is inhibited by BHB (Fig. 1). Surprisingly, and
opposite to GABA and GABOB, SMIT1 was insensitive to BHB
when in complexes with KCNQ3*, but was BHB-sensitive when
coupled with KCNQ2 (Fig. 4). SMIT1 therefore endows KCNQs
with an additional capacity to distinguish between GABA and
close structural orthologues that are both present endogenously in
the nervous system (BHB) and altered in a therapeutically/
pathologically relevant manner: BHB is the first ketone body
produced during fasting or ketogenic diets, and also in diabetic
ketoacidosis. Occipital lobe β-hydroxybutyrate concentrations
rise in children from around 50 µM at baseline to approximately
1 mM after 72 h of fasting31. SMIT1 both alters KCNQ selectivity
for BHB, and also amplifies the effects of clinically relevant
concentrations of BHB on KCNQ2/3, suggesting we should
consider KCNQ2/3–SMIT1 complexes when evaluating the
mechanisms underlying the therapeutic action of the ketogenic
diet and fasting in epilepsy.
We also show for the first time, to our knowledge, in this study
that GABA induces a distinct pore conformation, characterized
by increased relative permeability of Na+ and Cs+ relative to K+.
This new conformation only arises when GABA activates
KCNQs; it does not occur in homomeric KCNQ2 or KCNQ4
(Fig. 3), which bind GABA but are not activated by it8. These data
support an hypothesis in which rather than GABA simply shifting
the voltage dependence of KCNQ2/3 by favoring voltage sensor
movement more readily at a given membrane potential, GABA
actually induces a distinct pore conformation/activation state
with different voltage dependence than the GABA-free channel.
In summary, we demonstrate channel-transporter co-assembly
brings new properties to one or both entities within the complex,
and most strikingly, the channels act as chemosensors for their
partner transporters. This, to our knowledge, novel role for
potassium channels gives further clues to the evolutionary forces
that have brought channels and transporters together. It also has
additional ramifications for therapeutic targeting of either protein
type, beyond that mentioned above for BHB. For example, we
demonstrate that the anticonvulsant retigabine inhibits SMIT1
activity (via co-assembled KCNQ2/3) (Fig. 1). Retigabine was
removed from the clinic in 2017 because of side effects of
unknown mechanistic origin, including discoloration of the skin,
sclera and nails32. While the discoloration effects are unlikely to
occur because of SMIT1 modulation, other SMIT1-dependent
effects of retigabine and related compounds may either act
therapeutically or work against its intended activity, suggesting
that SMIT1 activity assays might be included when screening for
new KCNQ-opening anticonvulsants such that the possible
drawbacks and advantages can be fully investigated.
Methods
cRNA preparation and and X. laevis oocyte injection. cRNA transcripts
encoding human KCNQ2, KCNQ3, KCNQ4, or SMIT1 were generated as before8
by in vitro transcription using mMessage mMachine kits (Thermo Fisher Scien-
tific), after cDNA linearization. cRNA was quantified by spectrophotometry.
Mutant cDNAs were generated by site-directed mutagenesis using a QuikChange
kit according to manufacturer’s protocol (Stratagene, San Diego, CA) and the
corresponding cRNAs were prepared as above. We injected defolliculated stage V
and VI X. laevis oocytes (Ecocyte Bioscience, Austin, TX) with Kv channel α
subunit cRNAs (5–20 ng) and/or SMIT1 cRNA (10–20 ng). Oocytes were incu-
bated at 16 °C in Barth’s saline solution (Ecocyte) containing penicillin and
streptomycin, with daily washing, for 3–5 days prior to TEVC recording and/or
radioligand uptake studies.
Radioligand uptake studies. For DRG studies, we conducted radiolabeled uptake
assays using myo-[2–3H(N)]inositol (American Radiolabeled Chemicals Inc.) on
whole, freshly isolated postnatal day 8 rat DRG purchased from BrainBits
(Springfield, Illinois). DRG were removed from the Hibernate AB storage solution
(BrainBits) and placed into NbActiv4 medium (BrainBits) containing 25 ng/ml of
nerve growth factor and incubated overnight at 37 °C. Isolated DRG were cut into
5 mm pieces and placed in 1 ml Eppendorf tubes containing NbActiv4 medium
(200 μl per tube). Depending on experimental conditions the medium contained
myo-[2–3H(N)]inositol (3 μCi/ml) alone or with 100 µM GABA (Sigma). After
30 min at room temperature, DRG were washed two to three times in 3 ml of fresh
Fig. 4 SMIT1–KCNQ complexes KCNQ-isoform dependently distinguish between GABA and related metabolites. All error bars indicate SEM. a Mean
traces showing currents generated by KCNQ3* alone or with SMIT1 (n= 8). b Mean peak currents for KCNQ3* alone (black) or with SMIT1 (red)
quantified from traces as in (a) (n= 8). c Mean peak tail currents for KCNQ3* alone (black) or with SMIT1 (red) quantified from traces as in (a) (n= 8).
d Mean G/Gmax relationship for KCNQ3* alone (black) or with SMIT1 (red) quantified from traces as in (a) (n= 8). e Effects of SMIT1 on KCNQ3*
activation rate quantified as a single exponential fit, time constant= τact (n= 8). *p < 0.05. f Mean EM of unclamped oocytes expressing KCNQ3* alone
(black) or with SMIT1 (red) (n= 8). *p < 0.05. g Representative traces from KCNQ2 (Q2) in 100mM K+ (voltage protocol inset). h Mean current–voltage
relationship for Q2 in 100mM K+ (black), Cs+ (blue), Rb+ (red), and Na+ (magenta), in the absence or presence of SMIT1 as indicated; quantified from
traces as in (g); n= 5. i Estimated mean permeability relative to that of K+ versus ionic radius (Pauling) through Q2 in the absence (black) and presence
(blue) of SMIT1; n= 5. *p < 0.05; **p < 0.01. j Representative traces from KCNQ3* (Q3*) in 100mM K+ (voltage protocol as in (g)). k Mean
current–voltage relationship for Q3* in 100mM K+ (black), Cs+ (blue), Rb+ (red), and Na+ (magenta), with/without SMIT1 as indicated; quantified from
traces as in (j); n= 4. l Estimated mean permeability relative to that of K+ versus ionic radius (Pauling) through Q3* with (red) or without (black) SMIT1;
n= 4. **p= 0.006. m [3H]Myo-inositol uptake (30min) for oocytes expressing KCNQ2 and SMIT1 in the absence or presence of neurotransmitters/
metabolites indicated (100 µM) ([3H]Myo-inositol n= 10; GABA n= 16; BHB n= 17; GABOB n= 13). n [3H]Myo-inositol uptake (30min) for oocytes
expressing KCNQ3* and SMIT1 with/without neurotransmitters/metabolites indicated (100 µM) ([3H]Myo-inositol n= 17; GABA n= 10; BHB n= 8;
GABOB n= 16).
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Fig. 5 KCNQ2/3 channels require an arginine at the foot of the voltage sensor for communicating GABA binding to SMIT1. All error bars indicate SEM.
a Topology of KCNQ3 (two of four subunits shown) showing positions of W265 (red) and R242 (yellow) and segment numbering. VSD voltage-sensing
domain. b Structural model of KCNQ3 showing positions of W265 and R242. Color coding as in (a). c Mean traces showing currents generated by
KCNQ2–W236L/KCNQ3–W265L (Q2WL/Q3WL) (n= 8) alone or with SMIT1 (n= 7) in Xenopus oocytes. d Mean peak currents for KCNQ2–W236L/
KCNQ3–W265L (Q2WL/Q3WL) alone (black; n= 8) or with SMIT1 (red; n= 7) quantified from traces as in (c). e Mean peak tail currents for
KCNQ2–W236L/KCNQ3–W265L (Q2WL/Q3WL) alone (black; n= 8) or with SMIT1 (red; n= 7) quantified from traces as in (c). f Mean G/Gmax
relationship for KCNQ2–W236L/KCNQ3–W265L (Q2WL/Q3WL) alone (black; n= 8) or with SMIT1 (red; n= 7) quantified from traces as in (c). g Mean
EM of unclamped Xenopus oocytes expressing KCNQ2–W236L/KCNQ3–W265L (Q2WL/Q3WL) alone (black) (n= 8) or with SMIT1 (red) (n= 7). **p <
0.01. h Mean traces showing currents generated by KCNQ2–R213A/KCNQ3–R242A (Q2RA/Q3RA) alone (n= 14) or with SMIT1 (n= 16) in Xenopus
oocytes. i Mean peak prepulse and peak tail currents for KCNQ2–R213A/KCNQ3–R242A (Q2RA/Q3RA) alone (black; n= 14) or with SMIT1 (red; n= 16)
quantified from traces as in panel (h). j Mean EM of unclamped Xenopus oocytes expressing KCNQ2–R213A/KCNQ3–R242A (Q2RA/Q3RA) alone (black)
(n= 14) or with SMIT1 (red) (n= 16). k [3H]Myo-inositol uptake (30min) for Xenopus oocytes expressing subunits indicated in the absence or presence of
GABA (100 µM) as indicated (SMIT1 alone, n= 19; Q2RA/Q3RA-S1, n= 29; Q2RA/Q3RA-S1+GABA, n= 32).
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-0820-9 ARTICLE
COMMUNICATIONS BIOLOGY |            (2020) 3:90 | https://doi.org/10.1038/s42003-020-0820-9 | www.nature.com/commsbio 9
NbActiv4 medium containing 1 mM cold myo-inositol (Sigma), followed by 1–2
washes in 3 ml NbActiv4 medium. DRG were homogenized over a period of 6 h in
100 μl of 2% sodium dodecyl sulfate (SDS) in NbActiv4; each homogenized DRG
section was then transferred to a scintillation vial (1 DRG section per vial) con-
taining Ready Protein Plus scintillation fluid (Beckmann Coulter) (6 ml). Vials
were capped, shaken vigorously, and then allowed to sit at room temperature for at
least 30 min before scintillation counting in a Beckmann Coulter 6500. Each
experiment was performed on two batches of DRG from different deliveries; each
experiment always contained intra-batch controls and results presented are pooled
data from both batches.
For oocyte studies, we conducted radiolabeled uptake assays using myo-[2–3H
(N)]inositol (American Radiolabeled Chemicals Inc.) 5 days after oocyte cRNA
injection. For each condition/expression group, oocytes were placed in a round-
bottomed, 10-ml culture tube, washed, and resuspended in ND96 (200 μl per tube)
containing myo-[2–3H(N)]inositol (3 μCi/ml) with or without GABA, glutamate, β-
Hydroxybutyric acid (BHB), GABOB (Sigma), or retigabine (Tocris) at pH 7.5.
After 30 min at room temperature, oocytes were washed 2–3 times in 3 ml of ND96
containing 1 mM cold myo-inositol (Sigma), followed by 1–2 washes in 3 ml of
ND96. Oocytes were next individually placed in wells of a 96-well plate and lysed in
100 μl of 2% SDS in ND96; each lysed oocyte was then transferred to a scintillation
vial (1 oocyte per vial) containing Ready Protein Plus scintillation fluid (Beckmann
Coulter) (6 ml). Vials were capped, shaken vigorously, and then allowed to sit at
room temperature for at least 30 min before scintillation counting in a Beckmann
Coulter 6500. Each experiment was performed on several batches of oocytes from
different deliveries; each experiment always contained intra-batch controls and
results presented are pooled data from two or more batches.
Two-electrode voltage clamp (TEVC). We conducted TEVC recording at room
temperature as before8 with an OC-725C amplifier (Warner Instruments, Hamden,
CT) and pClamp8 software (Molecular Devices, Sunnyvale, CA) 3–5 days after
cRNA injection as described in section above. Oocytes were placed in a small-
volume oocyte bath (Warner) and viewed with a dissection microscope. Chemicals
were sourced from Sigma. Bath solution was (in mM): 96 NaCl, 4 KCl, 1 MgCl2, 1
CaCl2, 10 HEPES (pH 7.6). GABA and GABOB were stored at −80 °C as 1 M
stocks in molecular grade H2O and diluted to working concentrations on each
experimental day. BHB was stored at 4 °C as a 480 mM stock in 100% ethanol and
diluted to working concentrations each experimental day. All compounds were
introduced to the recording bath via gravity perfusion at a constant flow of 1 ml per
minute for 3 min prior to recording. Pipettes were of 1–2MΩ resistance when filled
with 3 M KCl.
Currents were recorded in response to pulses between −80 mV and +40 mV at
20 mV intervals, or a single pulse to +40 mV, from a holding potential of −80 mV,
to yield current–voltage relationships, current magnitude, and for quantifying
activation rate. TEVC data analysis was performed with Clampfit (Molecular
Devices) and Graphpad Prism software (GraphPad, San Diego, CA, USA); values
are stated as mean ± SEM. Normalized tail currents were plotted versus prepulse
voltage and fitted with a single Boltzmann function
g ¼ ðA1  A2Þ
1þ exp V1=2  V
 
=Vs
h in o
y þ A2
; ð1Þ
where g is the normalized tail conductance, A1 is the initial value at −∞, A2 is the
final value at +∞, V1/2 is the half-maximal voltage of activation and Vs the slope
factor. Activation and deactivation kinetics were fitted with single exponential
functions.
Relative permeability calculations. According to the Goldman–Hodgkin–Katz
(GHK) voltage equation
Erev ¼
RT=F ln PK½KþO þ PNa½NaO þ PCl½Cli
 
PK½Kþi þ PNa½Nai þ PCl½Clo
  ; ð2Þ
where Erev is the absolute reversal potential and P is permeability. This permits
calculation of the relative permeability of each ion if concentrations on either side
of the membrane are known. A modified version of this equation was used here to
determine relative permeability of two ions in a system in which only the extra-
cellular ion concentration was known. Thus, relative permeability of Rb+, Cs+, and
Na+ compared to K+ ions was calculated for all channels by plotting the I/V
relationships for each channel with each extracellular ion (100 mM) and comparing
them to that with 100 mM extracellular K+ ion to yield a change in reversal
potential (DErev) for each ion compared to that of K+. Permeability ratios for each
ion (X) compared to K+ were then calculated as
ΔErev ¼ Erev;X  Erev;K ¼
RT
zF
ln
PX
PK
: ð3Þ
Values were compared between channel types and statistical significance assessed
using ANOVA.
Chemical structures, in silico docking, and sequence analyses. Chemical
structures and electrostatic surface potentials (range: −0.1 to 0.1) were plotted
using Jmol, an open-source Java viewer for chemical structures in 3D: http://jmol.
org/. Illustrations of KCNQ structure were based on the X. laevis KCNQ1 cryoEM
structure33, which we altered to incorporate KCNQ3 residues known to be
important for GABA and mallotoxin binding8,20,21, followed by energy mini-
mization using the GROMOS 43B1 force field34, in DeepView35. Thus, X. laevis
KCNQ1 amino acid sequence LITTLYIGF was converted to LITAWYIGF, the
underlined W being W265 in human KCNQ3. In addition, X. laevis
KCNQ1 sequence WWGVVTVTTIGYGD was converted to WWGLITLATI-
GYGD, the underlined L being Leu314 in human KCNQ3. Surrounding non-
mutated sequences are shown to illustrate the otherwise high sequence identity in
these stretches. Structures are visualized in UCSF Chimera36.
Statistics and reproducibility. All values are expressed as mean ± SEM. One-way
ANOVA was applied for all other tests; if multiple comparisons were performed, a
post hoc Tukey’s HSD test was performed following ANOVA. All p values were
two-sided. Statistical significance was defined as p < 0.05.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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